CYP3A7 Antibody

What is CYP3A7 and why is it significant in research?

CYP3A7 is a member of the cytochrome P450 superfamily of enzymes that participates in drug metabolism and the synthesis of cholesterol, steroids, and other lipids. It plays a crucial role in drug metabolism, particularly in the biotransformation of various therapeutic agents, which is essential for determining drug efficacy and safety .

CYP3A7 is predominantly expressed in the fetal liver and is involved in the metabolism of steroids and other lipids, highlighting its importance in developmental pharmacology . The CYP3A gene family, which includes CYP3A4, CYP3A5, CYP3A7, and CYP3A43, is responsible for the metabolism of over 50% of clinically used drugs, making CYP3A7 a significant player in pharmacogenomics .

Understanding CYP3A7 function is vital for predicting individual responses to medications, especially in pediatric populations where expression can differ significantly from adults .

What applications are CYP3A7 antibodies validated for?

CYP3A7 antibodies have been validated for multiple laboratory applications:

Researchers should note that each antibody may not be validated for all applications, and optimization might be required when applying an antibody to a new experimental system .

What is the expected molecular weight of CYP3A7 in Western blot experiments?

An interesting discrepancy exists between the calculated and observed molecular weights for CYP3A7:

This discrepancy is important to note when interpreting Western blot results. The difference between expected and observed sizes could be attributed to post-translational modifications such as glycosylation or phosphorylation . When a protein sample contains different modified forms, multiple bands may be detected on the membrane .

How should CYP3A7 antibodies be stored and handled?

For optimal antibody performance and longevity:

• Store at -20°C in aliquots to avoid repeated freeze/thaw cycles

• Most commercial antibodies are provided in buffers containing glycerol (typically 50%) and stabilizers

• Before opening, briefly centrifuge the vial to collect the solution at the bottom

• When diluting for experiments, use fresh, cold buffer

• Typical working dilutions for Western blotting range from 1:500 to 1:2000, though optimal concentrations should be determined empirically

How can I distinguish between CYP3A7 and other CYP3A family members (especially CYP3A4) in my experiments?

This is a critical challenge since CYP3A7 shares 87% amino acid sequence identity with CYP3A4 . To ensure specific detection:

• Antibody selection: Use antibodies raised against unique regions of CYP3A7. For example, antibodies developed against the Pro344~Asp497 region have been used successfully for specific CYP3A7 detection .

• Validation controls: Include samples with known differential expression of CYP3A7 and CYP3A4:

  • Fetal liver samples (high CYP3A7, low CYP3A4)

  • Adult liver samples (typically low CYP3A7, high CYP3A4)

  • Adult liver samples carrying the CYP3A7*1C allele (potentially higher CYP3A7)

• Expression analysis validation: Consider complementing antibody-based detection with qPCR to distinguish between CYP3A isoforms at the mRNA level.

Studies have shown that approximately 1 in 10 adult livers express significant CYP3A7 protein (24-90 pmol/mg microsomal protein), contributing 9-36% to total CYP3A levels in these livers . This information can help in interpreting results from adult liver samples.

What positive controls should I use for CYP3A7 antibody validation?

For robust experimental design, consider these recommended positive controls:

When analyzing adult liver samples, note that the mean protein expression level of CYP3A7 was found to be 42 pmol/mg within the group of livers expressing CYP3A7 and 4 pmol/mg across all liver samples studied .

How can I optimize immunohistochemistry protocols for CYP3A7 detection in formalin-fixed, paraffin-embedded (FFPE) tissues?

For successful IHC detection of CYP3A7 in FFPE tissues:

• Antigen retrieval: Critical due to cross-linking caused by formalin fixation.

  • Heat-induced epitope retrieval (HIER) in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Optimize retrieval time (typically 15-20 minutes)

• Blocking and antibody conditions:

  • Use 3-5% BSA or normal serum from the same species as the secondary antibody

  • Primary antibody dilutions typically range from 1:50 to 1:500 for IHC

  • Incubation times: overnight at 4°C often yields best results with minimal background

• Detection systems:

  • For monoclonal antibodies like F19 P2 H2, a mouse IgG detection system is appropriate

  • Consider HRP/DAB or fluorescent detection based on your experimental needs

• Controls:

  • Include fetal liver as positive control

  • Adult liver can serve as low expression or negative control (unless from individuals with CYP3A7*1C allele)

  • Include antibody isotype controls to assess non-specific binding

What are the implications of CYP3A7 expression in adult tissues for drug metabolism studies?

This question addresses an important recent finding in pharmacology research:

High CYP3A7 protein expression was detected in approximately 10% of adult livers, contributing 9-36% to total CYP3A levels in these livers . This has several implications:

Researchers conducting drug metabolism studies should consider screening for CYP3A7 expression, especially when unexplained variability in metabolism is observed.

How should I approach CYP3A7 antibody selection for detecting both human and rodent (mouse/rat) proteins?

Cross-species reactivity is an important consideration:

• Sequence homology analysis: Human CYP3A7 shares varying degrees of homology with rodent CYP3A enzymes. When selecting antibodies:

  • Some polyclonal antibodies are reported to detect human, mouse, and rat CYP3A7

  • Verify the immunogen used to raise the antibody (some use recombinant fusion proteins of human CYP3A7)

• Validation experiments:

  • Western blot analysis using liver microsomes from all species of interest

  • For mouse/rat samples, include appropriate positive controls

  • Be aware that molecular weights may vary slightly between species

• Epitope considerations:

  • Antibodies raised against conserved regions are more likely to show cross-reactivity

  • Predicted reactivity information is sometimes provided (e.g., Human 99%, Rhesus Monkey 93%, Chimpanzee 94%)

It's worth noting that some antibodies specifically state reactivity with human, mouse, and rat CYP3A7 , making these good candidates for comparative studies across species.

What methodologies can be applied to study CYP3A7-mediated drug metabolism in neonates versus adults?

This research area is particularly important given that about 90% of drugs used for neonates and 70% of drugs used in the neonatal intensive care unit (NICU) are administered off-label .

Recommended methodology approaches include:

• In vitro metabolism studies:

  • CYP3A7 supersome assays (recombinant enzyme systems)

  • Age-specific liver microsomes (fetal, neonatal, adult)

  • P450-Glo assay for high-throughput screening of substrate/inhibitor activity

  • Metabolic stability assays with LC-MS/MS detection

• Comparative analyses:

  • Side-by-side comparison of CYP3A7 and CYP3A4 activity on drug candidates

  • Assessment of physicochemical properties of compounds that show CYP3A7 selectivity

    • Research suggests CYP3A7-selective compounds have slightly lower SlogP and topological polar surface area compared to CYP3A4-selective compounds

• Protein quantification in tissue samples:

  • Western blotting with validated CYP3A7 antibodies

  • Absolute quantification using isotope-labeled peptide standards and mass spectrometry

A comprehensive high-throughput screen revealed that CYP3A7 inhibition showed greater variety of ligands compared to CYP3A4, but only a small subset of compounds were capable of being metabolized by CYP3A7 . This difference in metabolic properties is particularly important in the neonatal setting where drugs approved for adults are administered to neonates.

What are the validated cell models for studying CYP3A7 function in vitro?

Researchers have several options for cellular models when studying CYP3A7:

When using these models, verification of CYP3A7 expression levels via western blotting with a validated antibody is recommended. For functional studies, it's important to assess CYP3A7 activity using selective substrates identified in high-throughput screening studies .

How can I determine whether a CYP3A7 antibody will be suitable for tissue microarray analysis in cancer research?

CYP3A7 expression has been reported in hepatocarcinoma and other cancer tissues , making it potentially relevant for cancer research. When evaluating antibodies for tissue microarray analysis:

• Validation for FFPE tissues:

  • Confirm the antibody is validated for immunohistochemistry with paraffin-embedded sections (IHCP)

  • Review published studies that have used the antibody on FFPE tissues

• Optimization protocol:

  • Test multiple antibody dilutions on positive control tissues

  • Compare staining patterns between:

    • Fetal liver (high CYP3A7 expression)

    • Adult liver (typically low expression)

    • Cancer tissues of interest

• Specificity verification:

  • Perform peptide competition assays to confirm binding specificity

  • Include isotype controls to assess non-specific binding

• Signal amplification considerations:

  • For potentially low expression in some cancer tissues, consider using signal amplification methods

  • Tyramide signal amplification may enhance detection sensitivity

Recommended antibodies include monoclonal antibodies like F19 P2 H2, which has been validated for immunohistochemistry with paraffin-embedded sections .

Why might I observe discrepancies between calculated and observed molecular weights when detecting CYP3A7 in Western blots?

The observed molecular weight of CYP3A7A in Western blots (approximately 75 kDa) differs from the calculated MW of 57-61 kDa . This discrepancy can be attributed to several factors:

• Post-translational modifications:

  • Glycosylation, phosphorylation, or other modifications can increase apparent molecular weight

  • CYP3A7 may undergo specific modifications in different tissues or developmental stages

• Protein structure influences:

  • Tertiary structure elements can affect migration in SDS-PAGE

  • Hydrophobic regions (common in CYP enzymes) may bind different amounts of SDS

• Technical considerations:

  • Buffer compositions and gel percentage can affect protein migration

  • Protein standards used for calibration may behave differently than CYP proteins

When a protein in a sample has different modified forms simultaneously, multiple bands may be detected on the membrane . If unexpected bands are observed, researchers should consider performing additional validation experiments, such as immunoprecipitation followed by mass spectrometry analysis.

What strategies can help differentiate between nonspecific binding and true CYP3A7 signal in immunodetection methods?

Distinguishing specific from nonspecific signals is critical for accurate CYP3A7 detection:

• Control samples:

  • Positive controls: Fetal liver tissue or HepG2 cells (known to express CYP3A7)

  • Negative controls: Samples known to lack CYP3A7 expression

  • Peptide competition: Pre-incubating antibody with immunizing peptide should eliminate specific binding

• Antibody validation:

  • Use multiple antibodies targeting different epitopes of CYP3A7

  • Compare monoclonal (higher specificity) vs. polyclonal (higher sensitivity) antibodies

  • Check for cross-reactivity with other CYP3A family members

• Protocol optimization:

  • Increase blocking concentration or time to reduce nonspecific binding

  • Optimize antibody dilution (too concentrated can increase background)

  • Include detergents like Tween-20 in wash buffers to reduce nonspecific hydrophobic interactions

• Complementary techniques:

  • Correlate protein detection with mRNA expression (RT-PCR)

  • Consider mass spectrometry-based validation for ambiguous results

Remember that in Western blotting applications, the molecular weight of detected bands should be critically evaluated against the expected (75 kDa observed) size of CYP3A7 .

How can I quantitatively assess CYP3A7 protein levels in human tissue samples?

For precise quantification of CYP3A7 in research samples:

• Western blot quantification:

  • Use recombinant CYP3A7 standards at known concentrations

  • Create a standard curve for each blot

  • Include reference proteins (e.g., β-actin, GAPDH) for normalization

  • Use fluorescent secondary antibodies for wider linear range of detection

• Mass spectrometry approaches:

  • Targeted proteomics using multiple reaction monitoring (MRM)

  • Use stable isotope-labeled peptide standards specific to CYP3A7

  • Select peptides unique to CYP3A7 (not shared with CYP3A4)

• Immunoassay methods:

  • ELISA with CYP3A7-specific antibodies

  • Automated capillary immunoassay systems (e.g., Wes, Jess)

Previous research established CYP3A7 protein expression levels in adult livers at approximately 42 pmol/mg within the group of livers expressing CYP3A7 and 4 pmol/mg across all liver samples studied . In livers with significant expression, CYP3A7 contributed 9-36% to total CYP3A levels, amounting to 24-90 pmol/mg microsomal protein . These values provide useful reference points for quantitative analyses.

How might CYP3A7 antibodies be used in developing targeted therapies for cancers with elevated CYP3A7 expression?

Elevated CYP3A7 expression has been reported in certain cancers , suggesting potential applications in cancer research and therapy:

• Diagnostic applications:

  • Development of immunohistochemistry panels to identify tumors with elevated CYP3A7

  • Potential prognostic marker based on correlation with clinical outcomes

• Drug development strategies:

  • Screening compounds that are preferentially metabolized by CYP3A7 to create tumor-targeted prodrugs

  • Identifying CYP3A7 inhibitors that could enhance efficacy of concurrent chemotherapeutics

  • Recent high-throughput screens have identified 22 CYP3A7-selective substrates over CYP3A4

• Personalized medicine approaches:

  • CYP3A7 antibody-based assays to stratify patients for clinical trials

  • Monitoring changes in CYP3A7 expression during treatment as a potential resistance marker

• Research applications:

  • Investigating the role of CYP3A7 in cancer cell metabolism

  • Exploring connections between CYP3A7 expression and steroid hormone-dependent cancers

As research continues to elucidate the role of CYP3A7 in various cancers, antibody-based detection methods will be crucial for both basic research and clinical applications.

What role might CYP3A7 antibodies play in developing better pediatric dosing guidelines?

The pronounced differences in drug metabolism between neonates and adults creates significant challenges in pediatric pharmacology:

• Developmental pharmacology research:

  • Quantifying CYP3A7 expression levels across developmental stages

  • Mapping the "isoform switching" from CYP3A7 to CYP3A4 during infant development

  • Correlating CYP3A7 levels with drug metabolism capacity in pediatric patients

• Precision medicine applications:

  • CYP3A7 genotype-phenotype correlation studies

  • Identifying patients with persistent CYP3A7 expression beyond infancy

  • Stratification for clinical trials based on CYP3A7 expression profiles

• Regulatory implications:

  • Supporting evidence for specialized pediatric formulations and dosing

  • Addressing the concerning statistic that about 90% of drugs used for neonates and 70% of drugs used in the NICU are administered off-label

• Drug development considerations:

  • Screening drug candidates for CYP3A7-mediated metabolism early in development

  • Identifying compounds with potential for age-dependent metabolism differences